Wedbush Estimates Xencor's Q3 Earnings (NASDAQ:XNCR)

Key Points

• Wedbush analysts have raised Xencor's Q3 2025 earnings estimate to ($0.51) per share from ($0.79), maintaining an "Outperform" rating with a target price of $26.00.
• Xencor reported quarterly earnings of ($0.41) EPS, outperforming the consensus estimate of ($0.78), with a year-over-year revenue increase of 82.4% to $43.61 million.
• Despite the positive earnings forecast, Barclays downgraded its target price for Xencor from $22.00 to $6.00 and set an "underweight" rating, reflecting varied analyst opinions on the stock.

Xencor, Inc. (NASDAQ:XNCR - Free Report) - Equities research analysts at Wedbush upped their Q3 2025 earnings estimates for shares of Xencor in a report issued on Thursday, August 7th. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will post earnings of ($0.51) per share for the quarter, up from their previous estimate of ($0.79). Wedbush currently has a "Outperform" rating and a $26.00 target price on the stock. The consensus estimate for Xencor's current full-year earnings is ($3.68) per share. Wedbush also issued estimates for Xencor's Q4 2025 earnings at ($0.84) EPS, FY2025 earnings at ($2.43) EPS, Q1 2026 earnings at ($0.86) EPS, Q2 2026 earnings at ($0.86) EPS, Q3 2026 earnings at ($0.86) EPS, Q4 2026 earnings at ($0.87) EPS, FY2026 earnings at ($3.45) EPS, FY2027 earnings at ($3.38) EPS and FY2028 earnings at ($3.75) EPS.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.37. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. The business had revenue of $43.61 million during the quarter, compared to analyst estimates of $22.59 million. During the same period in the previous year, the business posted ($1.07) EPS. The company's quarterly revenue was up 82.4% on a year-over-year basis.

A number of other research analysts have also issued reports on the stock. Barclays reduced their target price on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a research note on Thursday, May 8th. William Blair began coverage on shares of Xencor in a research note on Monday, April 21st. They set an "outperform" rating for the company. Finally, Wells Fargo & Company reduced their target price on shares of Xencor from $33.00 to $27.00 and set an "overweight" rating for the company in a research note on Thursday. Two investment analysts have rated the stock with a sell rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $26.43.

Xencor Stock Down 1.2%

Xencor stock opened at $7.23 on Monday. The firm has a 50-day moving average price of $8.67 and a two-hundred day moving average price of $10.87. The firm has a market capitalization of $515.64 million, a price-to-earnings ratio of -3.01 and a beta of 0.89. Xencor has a 52-week low of $7.07 and a 52-week high of $27.24.

Institutional Trading of Xencor

Institutional investors have recently made changes to their positions in the stock. Sterling Capital Management LLC raised its holdings in shares of Xencor by 732.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 1,040 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Xencor in the 4th quarter worth approximately $34,000. State of Wyoming bought a new stake in shares of Xencor in the 1st quarter worth approximately $34,000. CWM LLC raised its holdings in shares of Xencor by 195.5% in the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company's stock worth $36,000 after purchasing an additional 2,231 shares in the last quarter. Finally, Mackenzie Financial Corp bought a new stake in shares of Xencor in the 4th quarter worth approximately $101,000.

Insider Transactions at Xencor

In other news, Director Kurt A. Gustafson sold 2,993 shares of the company's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the sale, the director directly owned 20,183 shares of the company's stock, valued at approximately $186,087.26. This represents a 12.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Richard J. Ranieri sold 2,993 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $9.22, for a total transaction of $27,595.46. Following the completion of the sale, the director directly owned 19,183 shares of the company's stock, valued at approximately $176,867.26. This represents a 13.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 11,194 shares of company stock valued at $103,209. Company insiders own 5.23% of the company's stock.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.